IL-24对弥漫大B淋巴瘤临床治疗效果的预测价值  

Predictive value of IL-24 in the clinical treatment of diffuse large B cell lymphoma

作　　者：王帅[1] 朱晗[1] 曹蕾[1] 黄菲[1] 范磊[1] Wang Shuai;Zhu Han;Cao Lei;Huang Fei;Fan Lei(Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院血液科,江苏南京210029

出　　处：《南京医科大学学报（自然科学版）》2019年第11期1594-1597,1635,共5页Journal of Nanjing Medical University(Natural Sciences)

基　　金：国家自然科学基金(81670153)。

摘　　要：目的:探讨白介素24(interleukin,IL-24)对弥漫大B淋巴瘤临床治疗效果的预测价值。方法:选取82例弥漫大B淋巴瘤初诊患者,患者入院后均接受4个疗程利妥昔单抗联合环磷酰胺+阿霉素+长春新碱+泼尼松(cyclophosphamide,hydroxyldaunorubicin,oncovin,prednisone,CHOP)方案的常规一线治疗,根据病情转归情况分为治疗有效组(完全缓解及部分缓解)和治疗无效组(疾病稳定及疾病进展),同期选取66例健康体检者作为对照。通过ELISA检测受试人群外周血IL-24水平,并采用受试者工作特征(receiver operating characteristic,ROC)曲线评估IL-24对弥漫大B淋巴瘤临床治疗效果的预测价值。结果:治疗前,弥漫大B淋巴瘤患者的IL-24水平较健康体检者显著下降[(41.4±7.3)μg/mL vs.(62.3±9.3)μg/mL,P<0.001];治疗后,治疗有效组患者IL-24水平较治疗前显著增高[(55.0±7.0)μg/mL vs.(46.3±5.3)μg/mL,P<0.001],并且明显高于治疗无效组[(55.0±7.0)μg/mL vs.(36.5±4.2)μg/mL,P<0.001];治疗无效组患者治疗后IL-24水平较治疗前差异无统计学意义(P>0.05)。当取38.8μg/mL作为IL-24最佳临界值时,IL-24预测弥漫大B淋巴瘤患者临床治疗有效的灵敏度为95.65%,特异度为83.33%。结论:IL-24对弥漫大B淋巴瘤患者临床治疗效果具有可靠的预测价值。Objective:This study aims to investigate the value of interleukin 24(IL-24)in predicting the treatment outcomes of diffuse large B cell lymphoma(DLBCL). Methods:The 82 patients with DLBCL who were enrolled in our hospital were received 4 courses of rituximab combined with cyclophosphamide + hydroxyldaunorubicin + oncovin + prednisone(CHOP)routine first-line treatment. The patients were divided into the treatment-effective group(complete remission and partial remission)and the treatmentineffective group(stable disease and progressive disease)according to the treatment outcomes,and 66 healthy subjects were selected as the control group at the same time. The IL-24 level in peripheral blood of the tested population was analyzed by ELISA and the predictive value of IL-24 in the clinical treatment of DLBCL was evaluated by ROC curve. Results:Before treatment,the IL-24 levels in patients with DLBCL[(41.4±7.3)μg/mL]were significantly lower than those in healthy subjects[(61.4±9.3)μg/mL,P < 0.001]. In the treatment-effective group,the IL-24 level increased after treatment[(55.0±7.0)μg/mL vs.(46.3±5.3)μg/mL,P < 0.001],and was significantly higher than that in treatment-ineffective group[(55.0±7.0)μg/mL vs.(36.5±4.2)μg/mL,P < 0.001]. However,the IL-24 level in the treatment-ineffective group had no statistical difference after treatment(P > 0.05). When 38.8 μg/mL was taken as the IL-24 optimal threshold,the sensitivity and specificity of IL-24 to predict the effectivity of DLBCL treatment were 95.65% and 83.33%,respectively. Conclusion:IL-24 has a reliable predictive value in the clinical treatment of patients with DLBCL.

关 键 词：弥漫大B淋巴瘤 IL-24 治疗效果 

分 类 号：R733.4[医药卫生—肿瘤]